These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 21774931)

  • 1. Is a premature rise in luteinizing hormone in the absence of increased progesterone levels detrimental to pregnancy outcome in GnRH antagonist in vitro fertilization cycles.
    Dovey S; McIntyre K; Jacobson D; Catov J; Wakim A
    Fertil Steril; 2011 Sep; 96(3):585-9. PubMed ID: 21774931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum progesterone level effects on the outcome of in vitro fertilization in patients with different ovarian response: an analysis of more than 10,000 cycles.
    Xu B; Li Z; Zhang H; Jin L; Li Y; Ai J; Zhu G
    Fertil Steril; 2012 Jun; 97(6):1321-7.e1-4. PubMed ID: 22494924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists.
    Chung K; Krey L; Katz J; Noyes N
    Fertil Steril; 2005 Aug; 84(2):313-8. PubMed ID: 16084870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A premature luteinizing hormone surge without elevated progesterone levels has no adverse effect on cumulative live birth rate in patient undergoing a flexible GnRH antagonist protocol: a retrospective study.
    Zhang Y; Xu Y; Yu J; Wang X; Xue Q; Shang J; Yang X; Shan X
    J Ovarian Res; 2023 Jun; 16(1):119. PubMed ID: 37370146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer.
    Merviel P; Antoine JM; Mathieu E; Millot F; Mandelbaum J; Uzan S
    Fertil Steril; 2004 Jul; 82(1):119-25. PubMed ID: 15236999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF.
    Lainas T; Zorzovilis J; Petsas G; Stavropoulou G; Cazlaris H; Daskalaki V; Lainas G; Alexopoulou E
    Hum Reprod; 2005 Sep; 20(9):2426-33. PubMed ID: 15946995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study.
    Schachter M; Friedler S; Ron-El R; Zimmerman AL; Strassburger D; Bern O; Raziel A
    Fertil Steril; 2008 Oct; 90(4):1087-93. PubMed ID: 18023439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
    Weitzman VN; Engmann L; DiLuigi A; Maier D; Nulsen J; Benadiva C
    Fertil Steril; 2009 Jul; 92(1):226-30. PubMed ID: 18675961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization.
    Berin I; Stein DE; Keltz MD
    Fertil Steril; 2010 Feb; 93(2):360-3. PubMed ID: 19131055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in six trials.
    Griesinger G; Mannaerts B; Andersen CY; Witjes H; Kolibianakis EM; Gordon K
    Fertil Steril; 2013 Dec; 100(6):1622-8.e1-3. PubMed ID: 24083873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles.
    Kuang Y; Hong Q; Chen Q; Lyu Q; Ai A; Fu Y; Shoham Z
    Fertil Steril; 2014 Jan; 101(1):105-11. PubMed ID: 24161646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Premature progesterone rise negatively correlated with live birth rate in IVF cycles with GnRH agonist: an analysis of 2,566 cycles.
    Huang R; Fang C; Xu S; Yi Y; Liang X
    Fertil Steril; 2012 Sep; 98(3):664-670.e2. PubMed ID: 22704632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Premature Rise of Luteinizing Hormone Is Associated With a Reduced Cumulative Live Birth Rate in Patients ≥37 Years Old Undergoing GnRH Antagonist
    Gao F; Wang Y; Wu D; Fu M; Zhang Q; Ren Y; Yang Z; Shen H; Han H
    Front Endocrinol (Lausanne); 2021; 12():722655. PubMed ID: 34925227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration.
    Hugues JN; Massé-Laroche E; Reboul-Marty J; Boîko O; Meynant C; Cédrin-Durnerin I
    Fertil Steril; 2011 Sep; 96(3):600-4. PubMed ID: 21880277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An increased serum progesterone-to-estradiol ratio on the day of human chorionic gonadotropin administration does not have a negative impact on clinical pregnancy rate in women with normal ovarian reserve treated with a long gonadotropin releasing hormone agonist protocol.
    Lai TH; Lee FK; Lin TK; Horng SG; Chen SC; Chen YH; Wang PC
    Fertil Steril; 2009 Aug; 92(2):508-14. PubMed ID: 18701101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Premature luteinization and in vitro fertilization outcome in gonadotropin/gonadotropin-releasing hormone antagonist cycles in women with polycystic ovary syndrome.
    Segal S; Glatstein I; McShane P; Hotamisligil S; Ezcurra D; Carson R
    Fertil Steril; 2009 May; 91(5):1755-9. PubMed ID: 18394616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization-embryo transfer.
    Mitwally MF; Diamond MP; Abuzeid M
    Fertil Steril; 2010 Feb; 93(2):554-69. PubMed ID: 19362305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.